Extending cancer patients lives by making sure the right person, takes the right drug, at the right time.
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
Today’s healthcare system is in a crisis and it is largely due to the one size fits all treatment for late stage diseases. The top ten highest-grossing drugs in the United States helps as low as 1 in 25 of the people who take them. In 2011, it is estimated that over $350B was wasted in US healthcare. But there is an answer…Precision Medicine.
Precision Medicine is when the right person takes the right drug at the right time. However, Precision Medicine only happens when a diagnostic test is paired with a therapeutic to ensure the patient’s genetic profile is a match for the particular drug. This pairing is called a Companion Diagnostic.Companion Diagnostics enable Precision Medicine, so in the future, you will not speak of one without the other.
Precision Medicine is transforming Cancer Care and is at It’s Tipping Point
- 42 percent of all drugs in the pipeline have a companion diagnostic
- Oncology leads the way with 73 percent of the pipeline represented by precision medicine
- Entire Precision Medicine Ecosystem Benefits: Patients, Payers, Physicians, Pharma Cos
Precision Medicine and Companion Diagnostics are the driving forces behind eradicating cancer and will serve as a major catalyst in reducing the cost of healthcare in America.
Running on Cellgen’s proprietary platform, each disposable test will yield inclusion / exclusion data, while also leveraging proprietary machine learning algorithms to deliver intelligent, quantitative and actionable results to oncologists in under 5 hours as opposed to the current standard of 10-14 days. This information will help inform patients, physicians, oncologists, and others on how best to simplify and optimize life-saving clinical protocols.
Designed to detect DNA, RNA, and Proteins, Cellgen’s platform features a proprietary on-chip enrichment and detection workflow perfectly suited to be installed as the premier Companion Diagnostic testing system within leading oncology clinics globally.
IMMENSE MARKET OPPORTUNITY FOR COMPANION DIAGNOSTICS
The global companion diagnostics market is expected to grow at a 22.7% CAGR reaching $8.7 billion by 2019. Advancing molecular technologies, the encouragement/requirement by the FDA for companion diagnostics and the increasing costs of traditional drug discovery will continue to increase the adoption of companion diagnostics.
Cellgen will initially adopt a “Companion Similar” Market Strategy. We will target (or duplicate) established companion diagnostic tests which are already on the market and present a significant market opportunity. This strategy De-risks the venture by removing lengthy and expensive biology clinical trials. We will actively validate proven Biomarkers on the Cellgen platform. Our less invasive, less expensive and much faster platform will be welcomed by the marketplace.
WHAT KEY OPINION LEADERS ARE SAYING…
“ONCOLOGY IS ON FIRE WITH [PERSONALIZED MEDICINE], WITH TREATMENT SELECTIONS BASED ON INDIVIDUAL MOLECULAR CHARACTERISTICS. THIS IS ALSO HAPPENING WITH CHRONIC INFECTIOUS DISEASES, AND GENETIC DISEASES ARE NOT FAR BEHIND”
—Janet Woodcock, Director
Center for Drug Evaluation and Research,
U.S. Food and Drug Administration
Negotiating license with Lawrence Livermore Labs to acquire 4 patents and 1000+ validated infectious disease probes for our platform.
Exclusively licensed a novel electrochemical platform to monitor the response of immunotherapy from Oakland University.
Signed Partnership Agreement with University of Portsmouth in the UK to jointly work on the development of Immunotherapy assays.
Signed Option agreement to Acquire Machine Learning Algorithms from Rockefeller University
Developed Automated Robot to perform in house Lab-Developed-Tests (LDTs)
Collaborated with Johns Hopkins University on the Development of a panel of diagnostic tests.
Transferred Tech to Corporate Lab
Opened Corporate lab
Licensed Technology from UCSD